Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

29 Mar 2010

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

The U.S. Food and Drug Administration is working with state health officials from Mississippi and Louisiana to notify consumers, food service operators and retailers nationwide about an outbreak of norovirus associated with oysters recently harvested from an area near Port Sulphur, La. known as Area 7. The oysters were sold or distributed nationwide.

27 Mar 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

26 Mar 2010

ScinoPharm announces record results for fiscal year 2009

ScinoPharm, an active pharmaceutical ingredient specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008.

25 Mar 2010

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.

25 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Walgreens today announced earnings and sales for the second quarter of fiscal year 2010.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010

Effective defense against HIV: Acne drug minocycline

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

20 Mar 2010

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering and concurrent private placement of its common stock, resulting in net proceeds to Lexicon of approximately $181.4 million after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

20 Mar 2010

BioTrends publishes new LaunchTrends report on Actemra

BioTrends is pleased to announce the publication of a new syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis. This report is the first in a three wave series and is derived from on-line survey responses from 77 rheumatologists and qualitative interviews with 20 rheumatologists.

19 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Acne drug prevents HIV breakout

18 Mar 2010

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

Lung transplant patients may one day benefit from synthetic peptide, researchers report

NYU researchers identify novel therapy for rheumatoid arthritis

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

ScinoPharm announces record results for fiscal year 2009

Biogen Idec and Elan begin comparative trial of MS treatments

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

ChemoCentryx undertakes Phase II clinical trial of CCX140

AARDA launches campaign on family AQ

EUREKA project develops unique range of antibodies

Effective defense against HIV: Acne drug minocycline

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

BioTrends publishes new LaunchTrends report on Actemra

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Survey unveils impact of gene regulation on human health

Acne drug prevents HIV breakout

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in